Infant formula maker Bellamy's Australia is focused on submitting a formal application for regulatory approval of its Chinese labelled product by the end of the year and upgrading its capacity, chief executive Andrew Cohen says.
Revenue in the second half of the current financial year is expected to be lower than in the first half because sales of its Chinese labelled product will cease due to delays in obtaining registration from the China Food and Drug Administration, Mr Cohen told the company's annual general meeting.
Bellamy's will also look to realise further cost reductions and reinvest in marketing, product development and supply chain flexibility, he said.
Share
